Pre-Conference Day

As radiopharmaceuticals advance toward regulatory approval and standard-of-care (SOC) designation, the demand for theranostic services is rapidly increasing. In response, the University Health Network (UHN), a major multi-site Canadian hospital system, has launched a strategic, interdisciplinary initiative to transition theranostics from clinical research to routine care. Guided by a multi-year implementation roadmap, UHN addresses critical elements such as infrastructure, reimbursement, capacity planning, fundraising, and governance. This approach draws on clinical trial expertise and industry partnerships to enable scalable, sustainable integration of theranostics into mainstream healthcare

• Key components of UHN’s multi-year roadmap for implementing theranostics as a standard of care
• Operational and systemic challenges in transitioning theranostics from research to routine clinical use
• The role of hospital–industry collaboration in scaling and sustaining a theranostics program

The development and administration of TRPs require a robust and efficient logistics and distribution framework. Due to the short half-lives of many medical isotopes, including Lu-177, Ac-225, I-131 & Pb-212, precise timing and temperature control are critical to ensure the efficacy and safety of these therapies. Delve into the complexities of isotope logistics, emphasising strategies to mitigate supply chain disruptions and enhance delivery reliability.

• Optimising Isotope Supply Chains: Implement multisupplier strategies and advanced tracking systems to ensure consistent isotope availability and timely delivery
• Navigating Regulatory and Safety Protocols: Adhere to stringent regulatory requirements and safety standards to maintain compliance and ensure patient safety during transportation
• Enhancing Distribution Efficiency: Utilise proximitybased distribution networks and real-time monitoring technologies to reduce transit times and maintain the integrity of radiopharmaceuticals